Under a tenth of individuals who could benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it issues its inaugural advice on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging broader and more equitable access to GLP-1 medication.
Based on estimates, over two billion will be obese by 2030 if no action is taken.
"The new guidance recognises that excess weight is a chronic disease that can be addressed with thorough and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are major barriers to widespread access to the injections that can assist patients in reducing considerable weight, notes the body.
GLP-1 Therapy Scarcity
Even in the present best projected scenario, the manufacturing of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of the global need, as stated by the health organization.
The recommendation urges countries and companies to increase access, by strategies such as patent sharing.
A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
How Obesity Injections Function
The injections replicate a biological compound to delay gastric emptying, reduce hunger and boost feelings of fullness so individuals reduce food intake.
Patients commonly begin shedding pounds in the initial weeks of starting on the weekly injections.
Studies indicates users may see weight return within a year of halting the medication, as their normal hunger resume.
Being carrying excess weight elevates your chance for experiencing diseases, including type 2 diabetes, heart disease, stroke, and some cancers.
Obesity impacts individuals in all nations and was linked to millions of fatalities worldwide in 2024, per the WHO.
